893620-26-3

Basic information

• Product Name: Quinoline, 2,4,8-trichloro-7-methoxy-
• Synonyms: Quinoline, 2,4,8-trichloro-7-methoxy-;2,4,8-Trichloro-7-methoxyquinoline;8-trichloro-7-Methoxy-
• CAS NO: 893620-26-3
• Molecular Formula: C₁₀H₆Cl₃NO
• Molecular Weight: 262.52
• Mol File: 893620-26-3.mol

Chemical Properties

• Boiling Point: 348.5 °C at 760 mmHg
• Flash Point: 164.5 °C
• Appearance: /
• Density: 1.486
• Vapor Pressure: 0.000101mmHg at 25°C
• Refractive Index: 1.638
• PKA: -3.45±0.50(Predicted)
• CAS DataBase Reference: Quinoline, 2,4,8-trichloro-7-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 2,4,8-trichloro-7-methoxy-(893620-26-3)
• EPA Substance Registry System: Quinoline, 2,4,8-trichloro-7-methoxy-(893620-26-3)

Safety Data

• Hazardous Substances Data: 893620-26-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Quinoline, 2,4,8-trichloro-7-methoxy-, is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities, including anticancer, antimicrobial, and antifungal properties.
Used in Agrochemical Industry:
Quinoline, 2,4,8-trichloro-7-methoxy-, is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Dye Industry:
Quinoline, 2,4,8-trichloro-7-methoxy-, is used as an intermediate in the synthesis of dyes, providing a wide range of color options for various applications.
Used in Organic Synthesis:
Quinoline, 2,4,8-trichloro-7-methoxy-, is used as a building block in the synthesis of other complex organic compounds due to its versatile reactivity, enabling the creation of novel compounds with diverse applications.

InChI:InChI=1/C10H6Cl3NO/c1-15-7-3-2-5-6(11)4-8(12)14-10(5)9(7)13/h2-4H,1H3

Upstream product

• 141-82-2 malonic acid 
• 85893-87-4 2-chloro-3-methoxyaniline hydrochloride 
• 10025-87-3 trichlorophosphate 
• 113206-03-4 2-chloro-3-methoxyphenylamine 

Downstream Products

• 1108659-39-7 2,8-dichloro-7-methoxy-4-(4-methoxybenzyloxy)quinoline 
• 1108660-09-8 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline 
• 1180496-46-1 4-(4-methoxybenzyloxy)-8-chloro-7-methoxy-2-(4-methylthiazol-2-yl)quinoline 
• 1265883-39-3 C₂₄H₂₄ClN₃O₃ 

Relevant articles and documents

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease

Abstract We disclose here the synthesis of a series of macrocyclic HCV protease inhibitors, where the homoserine linked together the quinoline P2′ motif and the macrocyclic moiety. These compounds exhibit potent inhibitory activity against HCV NS3/4A protease and replicon cell based assay. Their enzymatic and antiviral activities are modulated by substitutions on the quinoline P2′ at position 8 by methyl and halogens and by small heterocycles at position 2. The in vitro structure activity relationship (SAR) studies and in vivo pharmacokinetic (PK) evaluations of selected compounds are described herein.

Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320

Exploration of the P2 region by mimicking the proline motif found in BILN2061 resulted in the discovery of two series of potent HCV NS3/4A protease inhibitors. X-ray crystal structure of the ligand in contact with the NS3/4A protein and modulation of the

MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.